This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rubin, L. J. Articles by Galiè, N. Search for Related Content PubMed Articles by Rubin, L. J. Articles by Galiè, N.

Pulmonary arterial hypertension: a look to the future

Lewis J. Rubin, MD^*,* and Nazzareno Galiè, MD

^* Pulmonary Vascular Center, University of California–San Diego School of Medicine, La Jolla, California, USA
Institute of Cardiology, University of Bologna, Bologna, Italy

Manuscript received January 29, 2004; accepted February 3, 2004.

^* Reprint requests and correspondence: Dr. Lewis J. Rubin, UCSD Medical Center, 9300 Campus Point Drive, M/C 7372, La Jolla, California 92037, USA.
ljrubin{at}ucsd.edu

The Third World Symposium on Pulmonary Arterial Hypertension served not only as a forum for the presentation of state-of-the art overviews of the pathobiologic and clinical aspects of pulmonary arterial hypertension (PAH), but also afforded an opportunity to the international scientific community to explore future directions of research and collaboration. This summary provides a brief overview of future directions in the field.

Abbreviations and Acronyms   BMPR2 = bone morphogenetic protein receptor-2   FPAH = familial pulmonary artery hypertension   PAH = pulmonary arterial hypertension   PDE5 = phosphodiesterase-5

This article has been cited by other articles:

				T. M. Bull, C. A. Meadows, C. D. Coldren, M. Moore, S. M. Sotto-Santiago, S. P. Nana-Sinkam, T. B. Campbell, and M. W. Geraci Human Herpesvirus-8 Infection of Primary Pulmonary Microvascular Endothelial Cells Am. J. Respir. Cell Mol. Biol., December 1, 2008; 39(6): 706 - 716. [Abstract] [Full Text] [PDF]

				H. H. Leuchte, C. Baezner, R. A. Baumgartner, D. Bevec, G. Bacher, C. Neurohr, and J. Behr Inhalation of vasoactive intestinal peptide in pulmonary hypertension Eur. Respir. J., November 1, 2008; 32(5): 1289 - 1294. [Abstract] [Full Text] [PDF]

				G. Warwick, P. S. Thomas, and D. H. Yates Biomarkers in pulmonary hypertension Eur. Respir. J., August 1, 2008; 32(2): 503 - 512. [Abstract] [Full Text] [PDF]

				National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Heart, March 1, 2008; 94(Suppl_1): i1 - i41. [Full Text] [PDF]

				National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41. [Full Text] [PDF]

				J. H. Newman, J. A. Phillips III, and J. E. Loyd Narrative Review: The Enigma of Pulmonary Arterial Hypertension: New Insights from Genetic Studies Ann Intern Med, February 19, 2008; 148(4): 278 - 283. [Abstract] [Full Text] [PDF]

				R. Voswinckel, B. Enke, F. Reichenberger, M. Kohstall, A. Kreckel, S. Krick, H. Gall, T. Gessler, T. Schmehl, H. A. Ghofrani, et al. Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension: Results From Randomized Controlled Pilot Studies J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1672 - 1681. [Abstract] [Full Text] [PDF]